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Summary
Objective Inactivating heterozygous mutations in the GCK gene
are a common cause of MODY and result in mild fasting hyper-
glycaemia, which does not require treatment. We aimed to iden-
tify the frequency, clinical and molecular features of GCK
mutations in a Turkish paediatric cohort.
Design and Patients Fifty-four unrelated probands were
selected based on the following criteria: age of diagnosis
≤17 years, family history of diabetes in at least two generations,
anti-GAD/ICA negative, BMI<95.p and follow-up with diet, oral
antidiabetic drug or low-dose insulin treatment (≤05U/kg/d). A
MODY probability score (www.diabetesgenes.org) was calculated
and 21 patients with a score ≥75%, HbA1c levels ≤75%
(585 mmol/mol) and fasting blood glucose (FBG) levels
99–145 mg/dl (55–80 mmol/l) were selected for Sanger
sequencing of the GCK gene. Targeted next-generation sequenc-
ing for all known monogenic diabetes genes was undertaken for
any patient without a GCK gene mutation.
Results GCK gene mutations (pathogenic or likely pathogenic
variants) and a novel intronic variant of uncertain significance
(c.208 + 3A>T) were identified in 13/54 probands (24%). Twelve
of these patients had a MODY probability score ≥75%. FBG level
and 2-h glucose level in OGTT were 123  14 mg/dl
(68  07 mmol/l) (107–157 mg/dl) and 181  30 mg/dl
(101  16 mmol/l) (136–247 mg/dl), respectively. Average of
glucose increment in OGTT was 58  27 mg/dl
(32  15 mmol/l) (19–120 mg/dl), and mean HbA1c level was
65  05% (475  55 mmol/mol) (59–76%). Five novel mis-
sense mutations were identified (p.F123S, p.L58P, p.G246A,
p.F419C, and p.S151C). Two patients treated with low-dose insu-
lin before the molecular analysis were able to stop treatment.
Conclusions Approximately 1 in 4 MODY cases in this Turk-
ish paediatric cohort have a GCK mutation. Selection of patients
for GCK gene analysis using the MODY probability score was an
effective way of identifying most (11/12) patients with a GCK
mutation.
(Received 13 October 2015; returned for revision 3 May 2016;
finally revised 22 May 2016; accepted 31 May 2016)
Introduction
Glucokinase (GCK) is the enzyme which catalyses the first step of
glycolysis and regulates insulin secretion as a glucose sensor.1,2
This enzyme is encoded by the GCK gene on chromosome
7p153-p151 comprising 12 exons and has three tissue-specific
isoforms due to three different-sized exon 1.3 Inactivating
heterozygous mutations in the GCK gene cause GCK-MODY
(maturity-onset diabetes of the young) that is characterized by
asymptomatic, nonprogressive and mild fasting hyperglycaemia
from birth.2,4 Glucose increment in oral glucose tolerance test
(OGTT) (0–120 min) is less than 54 mg/dl (3 mmol/l) in most
cases.5 HbA1c levels are just above the normal range and usually
between 56 and 73% (377–563 mmol/mol) in these patients.6
Microvascular and macrovascular complications are rare in
patients with GCK mutations, and pharmacological treatment is
rarely required.4,7
To date, there are no publications that investigate the fre-
quency of GCK mutations among MODY patients in the Turk-
ish population. In this study, we aimed to determine the
frequency of GCK mutations in a paediatric Turkish MODY
cohort and to identify the molecular and clinical characteristics
of GCK-MODY patients.
Material and methods
Patients and selection criteria
This study analysed 629 children with diabetes that were fol-
lowed up between 2000 and 2013 at Marmara University
Hospital, Department of Pediatric Endocrinology, Istanbul,
Turkey. Among them, 61 patients who had a clinical diagno-
sis of MODY were evaluated. Fifty-four of these patients
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(26 males and 28 females) with a mean age at diagnosis of
86  42 years consented to participate in this study and ful-
filled the inclusion criteria, which were the age of diagnosis
≤17 years, a minimum two-generation family history of dia-
betes, body mass index (BMI) <95th percentile at diagnosis,
negative tests for glutamic acid decarboxylase (GAD) and islet
cell (ICA) auto-antibodies and treatment with diet, oral
antidiabetic drug (OAD) or low-dose insulin treatment (≤05
U/kg/d) (Fig. 1). The clinical parameters such as birthweight,
BMI, HbA1c, fasting blood glucose (FBG), C-peptide and/or
insulin levels, standard oral glucose tolerance test (OGTT)
(2 h) and current treatment were recorded.
The genetic testing strategy is illustrated in Fig. 1. GCK
sequencing was performed in 21 patients with a FBG level
between 99 and 145 mg/dl (55–80 mmol/l), HbA1c levels
≤75% (585 mmol/mol) and MODY calculator scores ≥75% as
calculated on www.diabetesgenes.org. The description and evalu-
ation of the MODY probability calculator score has been
described in detail elsewhere.8 All patients without a GCK gene
mutation underwent targeted next-generation sequencing
(tNGS) analysis as described by Ellard et al.9in 2013.
Molecular and data analysis
DNA was extracted for all the probands using the AUTOPURE
LSTM nucleic acid purification instrument (©QIAGEN, Venlo,
Netherlands). After PCR amplification, the minimal promoter
region, exons 1–10 and flanking intronic regions of the GCK
gene (reference sequence NM_000162.3) were Sanger-sequenced
using an ABI 3730 DNA sequencer (©Applied Biosystems, Foster
City, CA, USA). Sequence alignment and variant calling were
performed using the Mutation Surveyor software (©SoftGenet-
ics, State College, PA, USA).
To determine the pathogenic status, in silico predictions were
performed using Alamut Visual, Interactive Biosoftware, Rouen,
France v2.7.2 software package. A set of different methods were
applied, which include SIFT, Align GVGD and PolyPhen-2 for
amino acid changes and SpliceSiteFinder-like, MaxEntScan,
NNSPLICE, GeneSplicer and Human Splicing Finder for splicing
predictions. Exome sequencing data generated by the ExAC
(Exome Aggregation Consortium) version 0.3 were also accessed.
Conservation analyses were performed in the UCSC Genome
Browser (http://genome.ucsc.edu/) using the Human GRCh38/
hg38 assembly as reference.
Family members of the probands who had a likely pathogenic
GCK variant were tested to check for cosegregation. Microsatel-
lite analysis was performed on families where the variant was
not detected in the proband’s parents. Novel variants were clas-
sified according to the ACMG guidelines.10
Targeted next-generation sequencing (tNGS) was performed
using an exon-capture assay with baits for 29 genes, as described
previously.9
The study was approved by the local ethical committee, and
the patients or their parents provided informed consent for the
study.
Results
Molecular genetic test results
A total of 21 probands of 54 unrelated possible MODY cases
were selected for GCK testing. Eleven different GCK patho-
genic or likely pathogenic variants were identified in 11/21
patients (52%). One additional GCK variant was identified by
a targeted next-generation sequencing assay for all known
monogenic diabetes genes in the remaining 43 patients. Each
proband was heterozygous for a different variant and these
included 10 missense and two splice site variants (Table 1).
We also found one novel synonymous exonic variant
(p.A173A) with no predicted impact on protein function or
mRNA splicing, which was therefore classified as a likely
benign variant of no clinical significance. Seven of the variants
have been reported previously in the literature (c.46-2A>G,
c.1254-1G>C, p.K169R, p.R191Q, p.V367M, p.R275C and
p.M393T).3,11–14 The remaining five (p.F123S, p.L58P,
p.G246A, p.F419C and p.S151C) are not listed in any publica-
tions collated by the online Human Gene Mutation Database
and were therefore classified as novel (Table 2). In addition,
we identified a novel intronic variant, c.208 + 3A>T, of uncer-
tain significance.
Testing of parental samples showed that the p.L58P variant
had arisen de novo and is therefore highly likely to be patho-
genic. Microsatellite analysis confirmed family relationships. InFig. 1 Study schematics indicating steps and selection criteria. OAD,
Oral antidiabetic drug.
© 2016 The Authors. Clinical Endocrinology Published by John Wiley & Sons Ltd.
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all other cases, the variants were inherited from a parent with
fasting hyperglycaemia characteristic of GCK MODY.
In silico analysis of the novel missense variants predicted
that five of the 6 are likely to be pathogenic, with p.G246A
classified as uncertain (Table 2). However, reports of other
mutations at this codon (p.G246)3,15,16 suggest that this resi-
due is important for enzymatic function and therefore this
variant is also likely to be pathogenic. Other mutations at
codons p.F123, p.S151 and p.F419 have been reported.3,17–19
The novel splice site variant c.208 + 3A>T was inherited from
the proband’s affected mother. It is predicted to disrupt the
sequence of the donor splice site of exon 2 and promote the
use of a neighbouring cryptic donor splice site ten bases
downstream (Fig. 2). Use of this splice site would result in
the inclusion of an additional ten nucleotides leading to a fra-
meshift and consequently to a premature termination codon
in exon 3. As a result, the mRNA is predicted to be degraded
by nonsense-mediated decay. Patient mRNA samples were not
available for analysis. Therefore, this variant was classified as
of uncertain significance.
Clinical features of the patients
We identified 12 patients with a GCK mutation (pathogenic
or likely pathogenic variant) and one variant of uncertain sig-
nificance. The frequency of GCK-MODY was 22% (12/54) in
the MODY cohort and 1.9% (12/629) in all diabetic children
who were followed in our hospital. With the exception of one
patient who was diagnosed via targeted next-generation
sequencing, all of the patients’ MODY calculator scores were
higher than 75%. The mean age of diagnosis was
79  52 years (04–158 years). The mean BMI was
172  19 kg/m2 (145–212 kg/m2), and all patients had nor-
mal weight, except for patient 8 (P8) who was overweight.
Average birthweight was 3270  860 g (1350–4800 g), but
three patients were born prematurely (Table 1).
Mean fasting blood glucose (FBG) level and 2-h glucose
level in OGTT were 123  14 mg/dl (68  07 mmol/l)
(107–157 mg/dl) and 181  30 mg/dl (101  16 mmol/l)
(136–247 mg/dl), respectively. Average 2-h glucose increment
in OGTT was 58  27 mg/dl (32  15 mmol/l) (19–120 mg/
dl), and only 50% (6/12) of the patients had an increment
less than 54 mg/dl (3 mmol/l). Mean HbA1c level at presenta-
tion was 65  05% (475  55 mmol/mol) (59–76%). Two
patients were treated with low-dose insulin (02–03 U/kg/d)
before the molecular analysis due to high glucose increment
in OGTT (91 and 120 mg/dl (51 and 666 mmol/l), respec-
tively). Patient 1 had the highest HbA1c level (max 76%
(596 mmol/mol)). His diabetic mother was also heterozygous
for the same GCK mutation and had developed diabetic
retinopathy (background retinopathy, <5 microaneurysms) at
the age of 32 years. After the genetic diagnosis of GCK
MODY was made, insulin treatment was discontinued in both
patients. Their mean HbA1c levels were 72/74%
(552/574 mmol/mol) and 62/63% (443/454 mmol/mol) on/
off insulin treatment, respectively.T
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Discussion
Molecular characteristics
We detected 12 pathogenic or likely pathogenic GCK variants
and one intronic variant of uncertain significance. These
include 6 previously unreported missense or splicing variants.
Two splice site mutations (c.46-2A>G and c.1254-1G>C) have
already been published as pathogenic.3,11 The novel variant
c.208 + 3A>G is predicted to affect the donor splice site of
exon 2 (Fig. 2). In silico analysis predicts that the new donor
splice site results in frameshift in the mRNA and causes a
premature stop codon, but studies of patient mRNA are
required to confirm this. The novel missense variants p.F123S,
p.G246A, p.F419C and p.S151C affect residues where other
mutations have been reported.3,15–19
In 12 probands, the GCK variant was inherited from a parent
with fasting hyperglycaemia. In the remaining family, the novel
p.L58P variant was shown to have arisen de novo. Interestingly,
a study by Baltrusch et al.20has investigated the interaction
between glucokinase and glucokinase-regulating protein (GRP).
This protein is mainly expressed in the hepatocytes, but its
interactions with glucokinase can reveal structural hotspots that
can disrupt glucokinase function if mutated. Their findings indi-
cate that the three-dimensional structure of glucokinase brings
the L58 and N204 amino acid residues to close vicinity. Their
interaction creates a motif crucial for the interaction with GRP.
Although this interaction does not have a direct link to the
persistent hyperglycaemia observed in our patient, it indicates
that the L58 amino acid residue is very important in the
three-dimensional folding of glucokinase. In addition, the N204
residue is part of the glucose-binding site of glucokinase.
Because of the close proximity between L58 and N204 in the
three-dimensional structure of glucokinase, a mutation in the
L58 may perturb the conformation at the active site and affect
the glucose binding to glucokinase.20
Clinical characteristics
A correct diagnostic approach and early diagnosis of GCK-
MODY is important to avoid unnecessary investigations and
pharmacological treatment. In this cohort of 54 Turkish paedi-
atric cases, 11 GCK mutations were identified in 21 suspected
GCK-MODY children (52%) and one GCK mutation in the
remainder of the cohort.
The frequency of GCK-MODY varies according to different
healthcare systems between countries which affect ascertainment.
Whereas its frequency in children with MODY is 83% in
Poland, it is 225%, 41% and 41% in Japan, Spain and Italy,
respectively.12,21–23 Approximately 1 in 4 MODY cases (24%) in
this cohort are due to GCK mutations. A recent study showed a
minimum population prevalence of 1 in 1000 in the Atlantic-
DIP study.24
Genetic testing is the gold standard for diagnosis of GCK-
MODY and is cost-effective in clinically selected patients.25 Selec-
tion techniques such as the MODY probability calculator can
assist with the identification of those patients most likely to have a
GCK mutation.8 In this study, GCK analysis was performed only
for the patients with fasting blood glucose between 99 and
145 mg/dl (55–80 mmol/l), HbA1c levels ≤75% (585 mmol/
mol) and a MODY calculator score ≥75%. This strategy proved
effective as a high frequency of GCK mutations was detected in
this group (52%) but only one GCK mutation in the rest of the
cohort. This unusual patient had a low MODY probability
Fig. 2 The In silico analyses’ result of the novel c.208 + 3A>T splice side mutation. Alamut v23 screen view showing the effect of the novel mutation
c.208 + 3A>T on the donor splice site of exon 2 of the GCK gene. Arrow is indicating the reduced/missing predicted scores for this splice site due to
the mutation. Ten nucleotides to the right appears a predicted cryptic donor splice site, which is potentially used instead of the existing splice site.
© 2016 The Authors. Clinical Endocrinology Published by John Wiley & Sons Ltd.
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calculator score (15%) due to insulin treatment at diagnosis. The
other patient who was currently on insulin treatment did not start
insulin treatment until 1 year later after diagnosis, so the MODY
calculator score was >75%.
The glucose increment in OGTT is less than 54 mg/dl
(3 mmol/l) in 70%5 and 83 mg/dl (46 mmol/l) in 95% of
patients with GCK-MODY (Ellard and Hattersley, unpublished
data). Only two mutations have been reported that cause excep-
tionally high postprandial glucose levels.26 Additionally, HbA1c
levels are lower in GCK-MODY than other types of MODY and
diabetes.4 In a recent study, HbA1c reference range in
GCK-MODY children was 56–73% (377–563 mmol/mol) and
provided good sensitivity and specificity for discriminating
hyperglycaemia likely to be caused by a GCK mutation.6
Although the HbA1c levels in this study were within expected
range except one, the glucose increments in OGTT were slightly
higher than expected.
The patients with GCK-MODY have similar incidence of micro-
or macrovascular complications compared with controls without
diabetes.7 Steele et al. reported that only diabetic retinopathy fre-
quency (30%) was higher than controls, but all were background
retinopathy that is not clinically significant.7 None of our patients
with GCK-MODY in our cohort had any micro- or macrovascular
complication, but the mother of P1 developed diabetic retinopa-
thy that did not require laser treatment.
Pharmacological treatment is not recommended in GCK-
MODY.4,27 Stride et al. found that GCK–MODY patients are
unresponsive to pharmacological therapy as a consequence of
their glucose sensing defect.27 In our cohort, only two patients
were treated with insulin at the time of genetic testing. The
pharmacological treatment was discontinued after the molecular
analyses and HbA1c levels did not rise when insulin treatment
was stopped.
This study provides first data about the frequency and molec-
ular–clinical features of GCK-MODY in a Turkish paediatric
population. It also demonstrates the utility of using clinical
characteristics in combination with a MODY probability score
to select patients with a very high likelihood of GCK-MODY.
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